IDO1 and melanoma: However, there are some ongoing phase 3 studies, such as nivolumab in combination with linrodostat (BMS-986205), a selective IDO-1 inhibitor, for the treatment of muscle-invasive bladder cancer (NCT03661320) and previously untreated metastatic/unresectable melanoma (NCT03329846).